Business

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the

articleGreenwich Lifesciences, Inc.September 28, 20215/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-to-partner-with-susan-g-komen-race-for-the-cure-houston
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

About this update from Greenwich Lifesciences, Inc.

[{"type":"text","content":" STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announces its partnership with the Susan G. Komen Race for the Cure® Houston event on Saturday, October 2, 2021.\n\nAs a Bronze level sponsor and partner, the Company will be managing a water station, supporting the event’s race map, and participating in the race. Vice President Clinical and Regulatory Affairs Jaye Thompson, PhD commented, “Greenwich is honored to be supporting the Race for the Cure. Stopping the negative impact of breast cancer requires not only the efforts of research but also requires education, screening, and support programs for patients and survivors such as those provided by the Komen organization. Our team is laced-up and ready to Race for the Cure!”\n\nSusan G. Komen®, the world’s leading breast cancer organization, will hold the 3.1 mile race in downtown Houston. Funds raised will help save lives from breast cancer and will help support Komen’s advocacy, research investments and support of people facing breast cancer today, ensuring everyone can get the care they need to live. Race participants are encouraged to go to komen.org/houstonrace to sign up and begin fundraising by securing sponsorships through family, friends and co-workers.\n\nCEO Snehal Patel added, “Our objective to prevent metastatic breast cancer recurrence naturally aligns very well with the Susan G. Komen foundation. While we are looking forward to participating in this local event in Houston, we also look forward to working with the national organization in the years to come to help improve the lives of breast cancer patients and survivors.”\n\nAbout Susan G. Komen\n\nSusan G. Komen is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. Komen advocates for patients, drives research breakthroughs, improves access to high-quality care, offers direct patient support and empowers people with trustworthy information. Founded by...

More updates from Greenwich Lifesciences, Inc.